Sepsis News and Research

Latest Sepsis News and Research

FDA finalizes new rule on donor eligibility for human tissues and cells

FDA today published a final rule establishing donor eligibility criteria for donors of human cells, tissues, and cellular and tissue-based products (HCT/Ps) to help prevent the transmission of communicable disease when these products are transplanted.

20 May 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

Breastfeeding helps against low weight infants and infection

A new study shows that human milk protects extremely low birth weight infants from developing sepsis -- an overwhelming infection and a leading cause of illness and death in these tiny babies.

1 May 2004

Time matters when treating fungal infections in newborns

A new UCLA study shows that ‘time matters’ when treating fungal infections in neonates and that earlier treatment can mean the difference between life and death.

1 May 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

Delirium in ICU patients a predictor of mortality

Between 60 percent to 80 percent of these patients develop a brain dysfunction known as delirium, which according to a group of physicians at Vanderbilt Medical Center is an independent predictor of mortality.

16 Apr 2004

British company to launch "super bug tester" into UK hospitals

MRSA is the first test to be developed from Acolyte’s BacLite® testing platform. BacLite reduces the time for identifying both the type of bacteria and, more importantly, the antibiotic sensitivity of the bacteria from the current 3-4 day standard to just 2-5 hours. This time advantage will mean clinicians will be able to treat, much more effectively, serious bacterial infections and prevent potentially fatal complications, such as sepsis and septic shock, from developing.

24 Mar 2004